Company / Capital Expenditures
AMICUS THERAPEUTICS, INC. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$3.3M
FY2025
5-year range
$3.3M / $7.4M
FY2021-FY2025
Trend
-7.2%
vs FY2024
Sector context
#85 of 194
Health Care
What the data says
At $3M, AMICUS THERAPEUTICS, INC.'s capital expenditures ranks #85 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $3M in FY2020 to $20M in FY2019.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of +0.4%.
Declined from $7M to $3M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -4.3%
- 5-Year CAGR
- +0.4%
- 10-Year CAGR
- -
Sector benchmark
#85 of 194 in Health CareTop 44% of 194This company $3.3M Sector average $117.5M
▼
-97.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.4%, indicating consistent growth.
- In FY2025, capital expenditures decreased 7.2% year-over-year.
- Ranks #85 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.3M | -7.2% |
| FY2024 | $3.6M | -52.2% |
| FY2023 | $7.4M | +97.6% |
| FY2022 | $3.8M | -3.0% |
| FY2021 | $3.9M | +20.4% |
| FY2020 | $3.2M | -83.9% |
| FY2019 | $20.0M | +217.2% |
| FY2018 | $6.3M | +39.4% |
| FY2017 | $4.5M | -23.9% |
| FY2016 | $6.0M | +23.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026